Stoke二季度更新复述zorevunersen三期进展和2028年潜在商业化路径

Trump insists Iran talks ongoing, says Hormuz could open ’literally by tomorrow’
Introduction & Market Context
Stoke Therapeutics (NASDAQ:STOK) presented its second quarter 2026 business update on August 3, highlighting significant progress toward a potential 2028 U.S. launch of zorevunersen, its experimental treatment for Dravet syndrome. The company’s shares closed the regular session at $29.59, up 2.53%, and remained essentially flat in after-hours trading at $29.56.
The presentation comes as Stoke transitions from a research-focused biotech to a company preparing for commercialization, with a pro-forma cash position of $420 million that management says will fund operations through the anticipated early 2028 launch.
Phase 3 EMPEROR Study: Enrollment Complete Ahead of Schedule
The company announced completion of Phase 3 enrollment in June 2026, achieving 162 patients across the U.S., UK, and Japan in just 10 months—exceeding the original target of 150 patients. According to the presentation, approximately 145 patients have completed through Week 8, about 80 through Week 24, and roughly 60 have reached Week 28, which represents the study’s primary endpoint for seizure frequency.
As illustrated in the following enrollment progression chart, the study has achieved a critical milestone with zero treatment discontinuations to date, compared to the 15% dropout rate assumed in the trial design.
Chief Executive Ian Smith emphasized the enrollment pace in the company’s earnings call: "The recent completion of enrollment of 162 patients in just 10 months speaks to the awareness and enthusiasm of zorevunersen and its potential to change the course of Dravet syndrome by addressing the underlying genetic cause of this disease."
The company expects Phase 3 data readout in Q3 2027, which will inform the completion of its rolling NDA submission planned for the second half of 2027.
The presentation outlined key progress across three strategic areas, as shown in this comprehensive overview:
Long-Term Efficacy Data Demonstrates Sustained Benefits
Stoke’s presentation featured compelling four-year open-label extension (OLE) data showing durable reductions in seizure frequency. The following chart illustrates median percentage changes in convulsive seizure frequency over 48 months of treatment:
Patients who received 70 mg doses in Phase 1/2a followed by up to 45 mg in the OLE demonstrated sustained median reductions in seizure frequency ranging from approximately 25% to 75% over the four-year period. The company noted that patients have now received treatment for more than five years, with over 930 doses administered across Phase 1/2 and OLE studies.
Chief Medical Officer Barry Ticho highlighted the significance of the longitudinal data: "These long-term longitudinal data, which include patients who have received up to 16 doses over a five-year period, offer insight into the ongoing benefits with chronic dosing."
Beyond seizure control, the presentation emphasized improvements in cognition and behavior. The following chart demonstrates continuing progress across key Vineland-3 subdomains measured as Phase 3 EMPEROR endpoints:
The data showed statistically significant improvements (p<0.01) in five key subdomains for each year compared to OLE baseline, including expressive and receptive communication, interpersonal relationships, personal skills, and coping abilities. The "Play and Leisure" subdomain showed the largest overall change, from 4.9 in Year 1 to 12.5 in Year 4.
These improvements are particularly meaningful given the natural history of Dravet syndrome. As illustrated in this conceptual trajectory comparison, neurodevelopment typically plateaus around age 2 in Dravet patients, creating a widening gap from neurotypical development:
Safety Profile Supports Long-Term Dosing
The presentation detailed zorevunersen’s safety profile across both Phase 1/2a studies (n=81) and open-label extension studies (n=75). The following safety summary shows the drug has been generally well-tolerated with long-term dosing:
In Phase 1/2a studies, 30% of patients experienced a study drug-related treatment-emergent adverse event (TEAE), with the most common being cerebrospinal fluid protein elevations (14%) and procedural vomiting (5%). In OLE studies, CSF protein elevation occurred in 94% of patients but was classified as a TEAE in only 59%, with no serious or severe clinical manifestations. Only one patient discontinued treatment due to elevated CSF protein.
Two deaths occurred during the OLE studies—one due to sudden unexpected death in epilepsy (SUDEP) and one due to malnutrition—both explicitly stated as unrelated to zorevunersen.
Regulatory Path and NDA Preparation
Stoke outlined a clear regulatory timeline toward potential U.S. approval. The company has scheduled a Pre-NDA meeting with the FDA for the second half of 2026 and plans to initiate a rolling NDA submission in Q1 2027, with completion targeted for H2 2027.
The following timeline illustrates the path from recent achievements through potential approval and launch:
The rolling submission sequence will begin with chemistry, manufacturing and controls in Q1 2027, followed by preclinical data in the first half of 2027, and clinical data including Week 52 results from EMPEROR in Q3 2027.
The presentation emphasized building confidence in zorevunersen’s value proposition through three key pillars: Phase 3 progress, longitudinal data, and visibility and credibility:
Notably, publication of zorevunersen data in The New England Journal of Medicine has enhanced awareness among healthcare professionals. Chief Patient Officer Jason Hoitt noted: "We know from market research that payers and healthcare providers already consider these data to be the most compelling evidence that we may have at the time of a potential approval."
Pipeline Expansion Beyond Zorevunersen
Stoke is advancing its pipeline beyond the lead Dravet program, with particular focus on STK-002 for autosomal dominant optic atrophy (ADOA). The following overview illustrates the disease characteristics and market opportunity:
ADOA is a progressive vision disorder caused by OPA1 haploinsufficiency, affecting approximately 1 in 30,000 people globally, with about 13,000 patients in the U.S., UK, EU-4, and Denmark. Between 65-90% of cases are caused by mutations in one allele of the OPA1 gene, and up to 46% of patients are registered legally blind.
The Phase 1 OSPREY study of STK-002 has completed dosing in the sentinel cohort and is continuing dose escalation, with initial data anticipated in the first half of 2027. The study design is detailed in the following chart:
The study involves intravitreal injection in one eye over a 48-week duration, testing single ascending doses of 0.1, 0.3, 0.5, and 0.7 mg/eye in 21 patients aged 18 to 54 years. Primary endpoints focus on safety, tolerability, and exposure, while secondary endpoints measure changes in visual function, ocular structures, quality of life, and electroretinographic measures.
Additionally, Stoke is conducting lead optimization to identify a clinical candidate for SYNGAP1-related disorders and has appointed Dr. Thomas McCauley as Chief Scientific Officer to support pipeline expansion.
Commercial Preparation and Market Opportunity
The presentation outlined a significant market opportunity for zorevunersen, with approximately 38,000 patients with Dravet syndrome across seven major geographic markets. The following chart breaks down the prevalence by region:
The U.S. represents about 16,000 patients, with another 16,000 in the EU-4 (Germany, France, Italy, and Spain) plus the UK, and 7,000 in Japan. The presentation emphasized that despite the availability of anti-seizure medicines, there are currently no disease-modifying treatments approved for Dravet syndrome.
Stoke highlighted favorable conditions for early adoption in the U.S. market, as shown in this market readiness summary:
Approximately 50% of identified U.S. patients are cared for by the top 50 sites, all of which have established intrathecal administration infrastructure. Additionally, about 50% of these top sites have already participated in zorevunersen clinical studies, providing familiarity with the treatment protocol.
A qualitative interview with a healthcare provider reinforced this readiness: "We’ve used Spinraza for years and we’ve already established the infrastructure of recurrent intrathecal injections for these patients. I can’t imagine that I’m going to need a completely different infrastructure."
Financial Position and Runway
Stoke reported a pro-forma cash position of $420 million as of the second quarter 2026, as illustrated in the following financial summary:
This figure comprises $354.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026, plus $65.7 million in net proceeds from a subsequent at-the-market stock sale of approximately 2.1 million shares.
According to the company’s earnings call, this financial position is anticipated to fund operations through potential U.S. commercialization of zorevunersen in early 2028. However, the company reported a wider-than-expected loss in Q2 2026, with adjusted earnings of negative $0.93 per share versus consensus estimates of negative $0.77. Revenue of $9.33 million significantly beat the forecast of $5.19 million, representing a 79.8% positive surprise.
The mixed quarterly results—a revenue beat offset by a larger loss—reflect the company’s continued heavy investment in research, development, and preparation for commercialization as it transitions toward a potential product launch.
Forward-Looking Considerations
While Stoke’s presentation outlined an ambitious path toward commercialization, several risks remain. The company still requires positive Phase 3 data before filing and approval, and the FDA could request additional data or changes to the submission package. Building a commercial infrastructure for launch and securing favorable reimbursement from payers for a rare disease therapy will also be critical challenges.
The stock’s performance remains heavily tied to zorevunersen’s success, making it particularly sensitive to any setbacks in the clinical or regulatory timeline. At the current price of approximately $29.56, shares trade about 132% above the 52-week low of $12.71 but remain about 26.5% below the 52-week high of $40.22.
Management has indicated plans for additional studies in infants and toddlers under 24 months and in adults with Dravet syndrome, expected to begin later in 2026, which could potentially expand the addressable patient population if zorevunersen receives approval.
The company’s ability to execute on its regulatory timeline and successfully transition to a commercial organization over the next 18 months will be critical factors for investors to monitor.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.